Manages levodopa/carbidopa. ANDA 74565, held by Chartwell Molecules. Selegiline Hydrochloride.
As of Nov 21, 2026, ANDA 74565 (Selegiline Hydrochloride), held by Chartwell Molecules, was first approved by FDA on Aug 2, 1996, with 7 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Selegiline Hydrochloride Tablets are indicated as an adjunct in the management of Parkinsonian patients being treated with levodopa/carbidopa who exhibit deterioration in the quality of their response to this therapy. There is no evidence from controlled studies that selegiline has any beneficial effect in the absence of concurrent levodopa therapy. Evidence supporting this claim was obtained in randomized controlled clinical investigations that compared the effects of added selegiline or placebo in patients receiving levodopa/carbidopa.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Aug 2, 1996 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Selegiline Hydrochloride5MG · tablet;oral | Selegiline Hydrochloride | Discontinued |
| Sep 4, 2025 | Supplement 8Labeling · Standard review | Approved | None posted |
| Jul 18, 2002 | Supplement 6Manufacturing | Approved | None posted |
| Apr 9, 2002 | Supplement 5Manufacturing | Approved | None posted |
| Sep 28, 1998 | Supplement 4Labeling | Approved | None posted |
| Jan 29, 1997 | Supplement 1Labeling | Approved | None posted |
| Jan 16, 1997 | Supplement 2Manufacturing | Approved | None posted |
| Jan 16, 1997 | Supplement 3Manufacturing | Approved | None posted |
| Aug 2, 1996 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters